

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of: See Schedule

Serial No.: See Schedule

Filed: See Schedule

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REVOCATION AND NEW POWER BY ASSIGNEE  
AND STATEMENT UNDER 37 C.F.R. §3.73(b)**

The Assignee (**Medical College of Georgia Research Institute, Inc.**) of the entire right, title, and interest in the applications listed in the attached Schedule A hereby revokes all previously granted powers and grants the registered practitioners of Cooley Godward Kronish LLP included in the Customer Number provided below power to act, prosecute, and transact all business in the U.S. Patent and Trademark Office in connection with these applications, any applications claiming priority to these applications, and any patents issuing therefrom.

The assignee certifies that to the best of its knowledge and belief it is the owner of the entire right, title, and interest in and to the applications identified in the attached Appendix A as evidenced by:

- An assignment document, a copy of which is enclosed herewith;
- An assignment previously recorded in the U.S. Patent and Trademark Office at the Reel/Frame indicated in the attached Schedule.

Please direct all telephone calls and correspondence to:

CUSTOMER NUMBER: **58249**

COOLEY GODWARD KRONISH LLP  
ATTN: Patent Group  
777 6<sup>th</sup> Street NW, Suite 1100  
Washington, DC 20001  
Tel: (202) 842-7800  
Fax: (202) 842-7899

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Date: 3/16/09

Signature: Betty Aldridge  
Name: Betty Aldridge  
Title: Executive Director  
Company: MCG Research Institute, Inc.  
Medical College of Georgia Research  
Institute, Inc.  
1120 15<sup>th</sup> Street  
Augusta, GA 30912

SCHEDULE A

| Docket Number                | MCG Number | Country | Serial Number | Title  | Filing Date | Reel/Frame  |
|------------------------------|------------|---------|---------------|--|-------------|-------------|
| NEWL-005/02US<br>142996-2008 | 009-03     | US      | 10/780,150    | Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2, 3-Dioxygenase  | 02/17/2004  | 014873/0966 |
| NEWL-005/03US<br>142996-2032 | 009-03     | US      | 12/175,518    | Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2, 3-Dioxygenase  | 07/18/2008  | 014873/0966 |
| NEWL-006/02US<br>142996-2007 | 009-03     | US      | 10/780,797    | Use of Inhibitors of Indoleamine-2, 3-Dioxygenase in Combination with Other Therapeutic Modalities | 02/17/2004  | 014844/0587 |
| NEWL-006/03US<br>142996-2033 | 009-03     | US      | 12/175,538    | Use of Inhibitors of Indoleamine-2, 3-Dioxygenase in Combination with Other Therapeutic Modalities | 07/18/2008  | 014844/0587 |